insights_auto
Why is 6160 up 4,36%?
Dive Deeperchevron_right
6160:HKG
BeOne Medicines AG
HK$225,00
arrow_upward
+4,36%(+9,40) 1D
16 Okt., 16:08:14 GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 6160...
Open
HK$224,80
High
HK$230,20
Low
HK$221,80
Mkt. cap
355,76Â mjd
Avg. vol.
2,93Â m
Volume
4,41Â m
P/E ratio
65,67
52-wk high
HK$235,60
52-wk low
HK$153,00
EPS
HK$3,43
Shares outstanding
1,43Â mjd
No. of employees
12Â k
Open
HK$224,80
High
HK$230,20
Low
HK$221,80
Mkt. cap
355,76Â mjd
Avg. vol.
2,93Â m
Volume
4,41Â m
P/E ratio
65,67
52-wk high
HK$235,60
52-wk low
HK$153,00
EPS
HK$3,43
Shares outstanding
1,43Â mjd
No. of employees
12Â k
News stories
From web sources and news partners
ad-hoc-news.de
·
12 uur gelede
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12Â k
Founded28 Okt. 2010
Headquarters-
Sector-
Websitebeonemedicines.com